The Florida Hospitals in Volusia and Flagler counties have each received a Get With the Guidelines performance achievement award from the American Heart Association and the American Stroke Association.
The award levels are based on measures designed to help hospital teams provide the most up-to-date, evidence-based guidelines with the goal of speeding recovery and reducing death and disability for stroke patients. They focus on appropriate use of guideline-based care for stroke patients, including aggressive use of medications such as clot-busting and anti-clotting drugs, blood thinners and cholesterol-reducing drugs, preventive action for deep vein thrombosis and smoking cessation counseling.
“The American Heart Association and American Stroke Association recognize Florida Hospital for its commitment to stroke care,” said Paul Heidenreich, M.D., M.S., national chairman of the Get With The Guidelines Steering Committee and professor of medicine at Stanford University. “Research has shown there are benefits to patients who are treated at hospitals that have adopted the Get With The Guidelines program.”
Florida Hospital Memorial Medical Center received the American Heart Association and American Stroke Association’s Get With The Guidelines Stroke Gold Plus quality achievement award with Target: Stroke Honor Roll Elite Plus. The award recognizes the hospital’s commitment to providing the most appropriate stroke treatment according to nationally recognized, research-based guidelines based on the latest scientific evidence.
To receive the Stroke Gold Plus quality achievement award, Florida Hospital Memorial Medical Center achieved an 85 percent or higher adherence to all Get With The Guidelines-Stroke achievement indicators for two or more consecutive 12-month periods and achieved a 75 percent or higher compliance with five of eight Get With The Guidelines-Stroke Quality measures.
To qualify for the Target: Stroke Honor Roll Elite Plus, Florida Hospital Memorial Medical Center met quality measures developed to reduce the time between the patient’s arrival at the hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke.